Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dendritic Cells | 6 | 2019 | 425 | 1.160 |
Why?
|
| Cytokines | 2 | 2025 | 1313 | 0.900 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 44 | 0.580 |
Why?
|
| Dog Diseases | 1 | 2019 | 57 | 0.570 |
Why?
|
| Doxorubicin | 1 | 2019 | 288 | 0.540 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 184 | 0.530 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 51 | 0.530 |
Why?
|
| Bystander Effect | 1 | 2016 | 5 | 0.500 |
Why?
|
| B7 Antigens | 1 | 2016 | 14 | 0.490 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 143 | 0.490 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 61 | 0.490 |
Why?
|
| Immunotherapy | 2 | 2019 | 727 | 0.470 |
Why?
|
| Cytosol | 1 | 2015 | 138 | 0.460 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 51 | 0.460 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 429 | 0.460 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 97 | 0.440 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2016 | 507 | 0.420 |
Why?
|
| Immunity, Innate | 1 | 2015 | 389 | 0.390 |
Why?
|
| Vaccines | 1 | 2017 | 379 | 0.380 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 535 | 0.360 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 657 | 0.350 |
Why?
|
| Fetal Blood | 4 | 2013 | 166 | 0.300 |
Why?
|
| Immunoassay | 1 | 2025 | 125 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2025 | 408 | 0.210 |
Why?
|
| Th1 Cells | 3 | 2017 | 148 | 0.200 |
Why?
|
| Adenoviridae | 2 | 2017 | 576 | 0.170 |
Why?
|
| Immunophenotyping | 3 | 2019 | 330 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2021 | 0.160 |
Why?
|
| Interferon-gamma | 3 | 2017 | 513 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 4419 | 0.150 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 98 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2015 | 2383 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 994 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2856 | 0.140 |
Why?
|
| Animals | 7 | 2019 | 33094 | 0.140 |
Why?
|
| Dogs | 1 | 2019 | 600 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2019 | 2896 | 0.140 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 69 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 114 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 281 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2016 | 46 | 0.120 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 312 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 479 | 0.120 |
Why?
|
| Monocytes | 2 | 2016 | 329 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 236 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 198 | 0.120 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 12 | 0.120 |
Why?
|
| CD3 Complex | 3 | 2013 | 88 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 57 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1228 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 2 | 2013 | 132 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 371 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 649 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1471 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2017 | 890 | 0.100 |
Why?
|
| Vaccination | 1 | 2019 | 994 | 0.100 |
Why?
|
| Cell Separation | 3 | 2011 | 218 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 471 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 53 | 0.090 |
Why?
|
| Antigens, CD34 | 2 | 2009 | 95 | 0.090 |
Why?
|
| Cell Movement | 1 | 2015 | 842 | 0.090 |
Why?
|
| Neoplasms | 2 | 2017 | 2814 | 0.090 |
Why?
|
| Macrophages | 1 | 2015 | 643 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 331 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 199 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 72 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 4495 | 0.080 |
Why?
|
| Antigens, CD | 3 | 2006 | 412 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 284 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1207 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 1689 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 1428 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 417 | 0.070 |
Why?
|
| Humans | 9 | 2025 | 125613 | 0.070 |
Why?
|
| Myocardium | 1 | 2011 | 835 | 0.060 |
Why?
|
| Bone Marrow Purging | 1 | 2006 | 33 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 615 | 0.060 |
Why?
|
| Mice | 4 | 2017 | 17528 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 498 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 79 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 261 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 101 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 903 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 225 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1848 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 1973 | 0.050 |
Why?
|
| Female | 3 | 2019 | 67790 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 926 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 452 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12334 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2017 | 505 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 269 | 0.040 |
Why?
|
| K562 Cells | 2 | 2013 | 93 | 0.040 |
Why?
|
| Pericytes | 1 | 2017 | 21 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 98 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2017 | 73 | 0.030 |
Why?
|
| Cell Survival | 2 | 2011 | 824 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 127 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 231 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 1 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 3 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2013 | 10 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 2006 | 669 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 228 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 285 | 0.020 |
Why?
|
| Male | 1 | 2019 | 61966 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 231 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 255 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 560 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 362 | 0.020 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 4 | 0.020 |
Why?
|
| Lymphography | 1 | 2011 | 11 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 88 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 33 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 32 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 342 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 370 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 174 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 782 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 333 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1159 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 200 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4668 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 351 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 780 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 312 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2558 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3436 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 47 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 363 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2006 | 49 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 46 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 39 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1095 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 2006 | 74 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3702 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2006 | 131 | 0.010 |
Why?
|
| Benzamides | 1 | 2006 | 117 | 0.010 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2006 | 51 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 824 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2006 | 74 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2006 | 191 | 0.010 |
Why?
|
| Piperazines | 1 | 2006 | 243 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1369 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 991 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 671 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2006 | 404 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 417 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 754 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 638 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 390 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 354 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1038 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6020 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3557 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4295 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 1154 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 1738 | 0.010 |
Why?
|